Education
About Us
Working with TipRanks
Follow Us
Xintela AB (DE:1XT)
FRANKFURT:1XT
1XT Stock Chart & Stats
€0.01
€0.00(0.00%)
At close: 4:00 PM EST
€0.01
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.01 - €0.05
Previous CloseN/A
Volume0.00
Average Volume (3M)1.67K
Market Cap
€22.77M
Enterprise Value€279.09M
Total Cash (Recent Filing)€3.38M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Feb 27, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding979,390,560
10 Day Avg. Volume5,000
30 Day Avg. Volume1,666
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)-31.80
Price to Sales (P/S)44.88
P/FCF Ratio-4.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Xintela AB News
1XT FAQ
What was Xintela AB’s price range in the past 12 months?
Xintela AB lowest stock price was €0.01 and its highest was €0.05 in the past 12 months.
What is Xintela AB’s market cap?
Xintela AB’s market cap is €22.77M.
When is Xintela AB’s upcoming earnings report date?
Xintela AB’s upcoming earnings report date is Feb 27, 2026 which is in 73 days.
How were Xintela AB’s earnings last quarter?
Xintela AB released its earnings results on Nov 04, 2025. The company reported >-€0.001 earnings per share for the quarter, beating the consensus estimate of -€0.002 by <€0.001.
Is Xintela AB overvalued?
According to Wall Street analysts Xintela AB’s price is currently Overvalued.
Does Xintela AB pay dividends?
Xintela AB does not currently pay dividends.
What is Xintela AB’s EPS estimate?
Xintela AB’s EPS estimate is >-0.01.
How many shares outstanding does Xintela AB have?
Xintela AB has 979,390,560 shares outstanding.
What happened to Xintela AB’s price movement after its last earnings report?
Xintela AB reported an EPS of >-€0.001 in its last earnings report, beating expectations of -€0.002. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Xintela AB?
Currently, no hedge funds are holding shares in DE:1XT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xintela AB
Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. The company develops products based on XINMARK, a patented marker technology that identifies and selects a range of stem cells, which can develop cartilage cells. It is also developing XSTEM a stem cell product that is in clinical development phase for the treatment of knee osteoarthritis and difficult-to-heal leg ulcers; and EQSTEM, a stem cell product for the treatment of joint diseases in horses, as well as focuses on the preclinical development of therapeutic antibodies for aggressive cancers, including brain tumor glioblastoma and triple negative breast cancer. Xintela AB (publ) was founded in 2009 and is based in Lund, Sweden.
Technical Analysis
Isofol Medical AB
―
Elicera Therapeutics AB
―
IRLAB Therapeutics AB Class A
―
Modus Therapeutics Holding AB
―
Active Biotech AB
―